Search the database for deliberate release of GM medicinal products
Displaying 1 - 4 of 4
|EU record number
|Company / Sponsor
|A phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or resistant B-NHL
|Miltenyi Biotech GmbH
|CD19 and CD20 chimeric antigen receptor
|A phase I, ascending dose, to evaluate safety and efficacy of ADP A2M4CD8 in HLA-A2+ patients with MAGE-A4 psoitives tumors
|MAGE-A4 specific T cell receptor (TCR) with a CD8α co-receptor
|Phase III trial investigating a AAV vector containing a variant of human factor IX gene administered to adult subjects with severe or moderately-severe hemophilia B
|uniQure biopharma B.V.
|Recombinant adeno associated viral vector containing the wild type modified to express the Padua derivative of human coagulation factor IX cDNA
|Evaluation of the safety and efficacy of the vaccine PB-116 in the control of porcine pleuropneumonia caused by Actinobacillus pleuropneumoniae
|Laboratorios Hipra S.A.
|no new genes but deletion of a segment of gene A from which depends the haemolytic activity of the pathogen